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Upregulation of mGlu2 Receptors via NF-jB p65
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Bruna Cuccurazzu1,2,4, Valeria Bortolotto1,2,4, Maria Maddalena Valente1,2, Federica Ubezio1,2,
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Acetyl-L-carnitine (ALC) is a naturally occurring molecule with an important role in cellular bioenergetics and as donor of acetyl groups to
proteins, including NF-kB p65. In humans, exogenously administered ALC has been shown to be effective in mood disturbances, with a
good tolerability profile. No current information is available on the antidepressant effect of ALC in animal models of depression and on
the putative mechanism involved in such effect. Here we report that ALC is a proneurogenic molecule, whose effect on neuronal
differentiation of adult hippocampal neural progenitors is independent of its neuroprotective activity. The in vitro proneurogenic effects of
ALC appear to be mediated by activation of the NF-kB pathway, and in particular by p65 acetylation, and subsequent NF-kB-mediated
upregulation of metabotropic glutamate receptor 2 (mGlu2) expression. When tested in vivo, chronic ALC treatment could revert
depressive-like behavior caused by unpredictable chronic mild stress, a rodent model of depression with high face validity and predictivity,
and its behavioral effect correlated with upregulated expression of mGlu2 receptor in hippocampi of stressed mice. Moreover, chronic,
but not acute or subchronic, drug treatment significantly increased adult born neurons in hippocampi of stressed and unstressed mice.
We now propose that this mechanism could be potentially involved in the antidepressant effect of ALC in humans. These results are
potentially relevant from a clinical perspective, as for its high tolerability profile ALC may be ideally employed in patient subpopulations
who are sensitive to the side effects associated with classical antidepressants.
Neuropsychopharmacology (2013) 38, 2220–2230; doi:10.1038/npp.2013.121; published online 5 June 2013
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INTRODUCTION
Although the role of adult hippocampal neurogenesis
remains to be fully elucidated, several studies suggest its
involvement in cognitive and emotional functions
(Kempermann, 2008; Aimone et al, 2011; Couillard-
Despres et al, 2011; Sahay et al, 2011) and its deregulation
in neuropsychiatric disorders, including major depression
disorder (MDD) (Hsieh and Eisch, 2010; Samuels and Hen,
2011). Based on the evidence that hippocampal neurogen-
esis can be downregulated by chronic stress, the hypothesis
has emerged that this process may contribute to MDD
pathophysiology (Pittenger and Duman, 2008; Hanson et al,
2011) and that it may be necessary for some of the effects of
antidepressants in rodents (Santarelli et al, 2003; David
et al, 2009) and humans (Boldrini et al, 2009). Endogenous
acetyl-L-carnitine (ALC), aside from its role in cellular
bioenergetics, modulates the activity of neurotrophic
factors, hormones, and neurotransmitters in nervous tissues
(Jones et al, 2010). Exogenously administered ALC can
readily pass the blood–brain barrier (Inano et al, 2003) and
it is neuroprotective at supraphysiological concentrations
(Jones et al, 2010). In addition, the antinociceptive effects of
ALC were demonstrated in rodent pain models (Chiechio
et al, 2006, 2009). In humans, and particularly in the elderly,
the beneficial effects of ALC were observed in mood
disorders (Tempesta et al, 1987; Garzya et al, 1990; Bella
et al, 1990; Zanardi and Smeraldi, 2006), with an unknown
mechanism of action. Surprisingly, no published studies
have evaluated, in animal models, the antidepressant
activity of ALC. The drug can act as a donor of acetyl
groups to proteins (Pettegrew et al, 2000), including the p65
member of NF-kB transcription factors (Chiechio et al,
2006), which are implicated in adult neurogenesis and
neuroplasticity (Denis-Donini et al, 2008; Koo et al, 2010;
Bonini et al, 2011; Grilli and Meneghini, 2012). Interest-
ingly, ALC modulates gene expression of metabotropic
glutamate receptor 2 (mGlu2) via NF-kB p65 acetylation
and this mechanism has been proposed for ALC-mediated
analgesic effects (Chiechio et al, 2006, 2009). Here we
explored the possibility that ALC may promote adult
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neurogenesis and mGlu2 upregulation via NF-kB pathway
activation and that this mechanism may contribute to its
antidepressant efficacy.
MATERIALS AND METHODS
Animals
Male 5-month-old C57B/L6J mice from Charles River
Laboratories (Calco, Italy) were utilized. Protocols were
reviewed and approved by the local ethical committee on
animal experimental studies.
Drugs
The following drugs were used: acetyl-L-carnitine and
L-carnitine (Sigma-Tau, Pomezia, Italy); LY487379 (Tocris
Bioscience, Bristol, UK); LY379268 and LY341495 (Ascent
Scientific, Cambridge, UK); and JSH-23, SC-514, SN-50, and
SN-50M (Calbiochem-Merck KGaA, Darmstadt, Germany).
Cell Cultures and Immunocytochemical Analysis
For adult hippocampal neural progenitor cultures, the
procedure for their maintenance, differentiation, and
determination of apoptotic/necrotic rate was described
elsewhere (Meneghini et al, 2010). To assess proliferation,
neural progenitors were cultured for 2–24–72 h in the
presence of ALC and vehicle. Bromodeoxyuridine (BrdU;
10 mM) was added to culture medium 2 h before cessation
of treatment and then cells were fixed with 4% PFA.
For immunofluorescence analysis, anti-BrdU (1 : 600, Novus
Biologicals, Littleton, CO), anti-MAP-2 (1 : 600, Chemicon,
Temecula, CA), anti-nestin (1 : 3000, Neuromics, Edina,
MN), anti-GFAP (1 : 600, Millipore, Billerica, MA), or
anti-NG2 (1 : 500, Abcam, Cambridge, UK) antibodies
were used.
Western Blot Analysis
A total of 30 mg proteins were separated onto 8–10% SDS-
PAGE gel. The primary antibodies used were: anti-mGlu2
(1 : 1000, Abcam), anti-mGlu3 (1 : 1000, Alomone Labs,
Jerusalem, Israel), anti-PAR-1 (1 : 1000, Santa Cruz Biotech-
nology, Santa Cruz, CA), anti-Acetyl-NF-kB p65 (Lys310)
(1 : 1000, Cell Signaling Technology, Danvers, MA), and
anti-NF-kB p65 (1 : 1000, Santa Cruz Biotechnology).
Densitometric analysis was performed by Quantity One
software (Bio-Rad Laboratories), with samples normalized
to a-tubulin (1 : 2000, Sigma Aldrich, Milan, Italy) or b-actin
signals (1 : 2000, Sigma Aldrich).
UCMS Procedure and Behavioral Assessment
Upon arrival, C57B/L6J male mice (n¼ 66, 4–5 month old)
were kept in the animal facility for 2 weeks before initiating
the experimental procedure. The first 8 weeks of the UCMS
regimen were drug free and treatment began from week 9 of
UCMS and continued up to the end of behavioral testing.
Vehicle (0.9% NaCl) or ALC (100mg/kg) were administered
s.c., once a day, for 3 weeks. In the first 5 days of treatment,
a subgroup of mice (n¼ 24) was also given a daily dose of
BrdU (150mg/kg, Sigma Aldrich, i.p.). The stress regimen
and behavioral analysis were applied as previously
described (Koo et al, 2010; Valente et al, 2012).
In Vivo Neurogenesis Studies
For assessing the effect of drug treatment on cell prolifera-
tion, mice were treated for 21 days with ALC (100mg/kg,
s.c.) or vehicle. In the last day of treatment, mice received
BrdU 150mg/kg i.p. and were killed 2 h later. For acute
(1 day) and subchronic (7 days) ALC treatment, mice were
treated with BrdU on the first day of drug treatment and
killed 21 days later. Mice were transcardially perfused and
brain tissue prepared for immunofluorescence analysis with
anti-BrdU (1 : 200; Novus Biologicals), anti-Neuronal Nuclei
(NeuN; 1 : 150; Millipore), and anti-glial fibrillary acidic
protein (GFAP; 1 : 100; Santa Cruz Biotechnology). Quanti-
fication of newborn hippocampal neurons and BrdUþ cells
was performed by modified unbiased stereology (Denis-
Donini et al, 2008).
ALC Plasma Measurement
Quantification of ALC plasma levels was performed in
samples from naive mice treated with vehicle and ALC
100mg/kg s.c. for 21 days (n¼ 6/group), as previously
described (Schaevitz et al, 2012).
Statistical Analysis
Data are reported as mean±SD. In experiments with only
two groups, Student’s t-test was used. For experiments with
more than two groups, data were analyzed by one-way
analysis of variance (ANOVA) followed by Tukey’s post hoc
test, or by a two-way ANOVA (using stress and treatment as
factors), followed by Bonferroni post hoc test. Statistical
significance level was set for P-values o0.05.
RESULTS
ALC Promotes Differentiation of Adult Hippocampal
NPC Toward the Neuronal Lineage
Nestinþ neural progenitor cells (NPCs) isolated from adult
mouse hippocampi can be maintained in an undifferen-
tiated proliferative state (Meneghini et al, 2013). Upon
removal of growth factors from medium, they stop dividing
and differentiate. By double immunolabeling for markers of
neurons (MAP-2) and undifferentiated progenitors (nestin),
the appearance of new neurons that are MAP-2þ and
nestin cells can be evaluated. Under these experimental
conditions, we tested the effects of ALC (0.01–1mM). The
drug significantly increased, in a concentration-dependent
manner, the percentage of MAP-2þ cells (F(5, 48)¼ 139.2,
Po0.0001; Figure 1a), with a maximal effect at 300 mM (%
increase over vehicle-treated cells: þ 148.9±22.8). Expo-
sure to 300 mM ALC also produced significant reduction of
GFAPþ astrocytes and NG2þ oligodendrocyte precursors
(% decrease over vehicle-treated cells:  47.4±8.4 and
 31.4±4 for GFAPþ cells (Po0.001) and NG2þ cells
(Po0.001), respectively; Figure 1b and c). In order to
investigate whether ALC promoted cell survival, we
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analyzed the number of apoptotic cells and the amount of
LDH released by necrotic cells in culture medium in the
presence of ALC or vehicle. Despite the fact that one-way
ANOVA revealed a difference in the apoptotic rate
(F(5, 48)¼ 6.181, P¼ 0.0002; Figure 1d), post hoc analysis
confirmed no significant difference in the comparison
between any ALC concentration and the vehicle group. No
difference was also observed in LDH activity in vehicle- vs
ALC-treated cultures (Figure 1e). In addition, exposure to
300 mM ALC for 2 and 72 h had no effect on the proliferation
rate of adult hippocampal neural progenitors, compared
with vehicle, as assessed by BrdU incorporation (Figure 1f).
Similarly, no significant difference was reported between
ALC and vehicle after 24 h of incubation (data not shown).
Figure 1 ALC proneurogenic effects on adult hippocampal neural progenitors involved activation of the NF-kB pathway and acetylation of p65. (a) The
24 h treatment with ALC (0.01–1mM) promoted neuronal differentiation from adult hippocampal NPCs by significantly increasing the percentage of MAP-
2þ cells as compared with vehicle (veh). (b, c) ALC (300 mM) significantly reduced the percentage of GFAPþ astrocytes (b) and NG2þ oligodendrocyte
precursors (c) derived from adult NPCs. (d, e) The percentage of apoptotic cells (d) and the amount of released LDH activity (e) were not significantly
different in ALC- vs vehicle-treated cells. (f) The 2- and 72-h incubation of proliferating neural progenitors with ALC 300 mM did not affect BrdU
incorporation as compared with vehicle-treated cells. BrdU (10 mM) was added to culture medium during the last 2 h of incubation. Data are expressed as
%BrdUþ cells over total viable cells. (g) NF-kB inhibitors JSH-23 (3mM ), SC-514 (3mM), and SN-50 (10 mg/ml) counteracted the proneurogenic effects of
300 mM ALC. The inactive peptide SN-50M (10 mg/ml) had no effect. Data are mean±SEM of n¼ 2 experiments in triplicate for (g) and n¼ 3 experiments
in triplicate for all the others. (h) The 0.3 and 1mM L-carnitine (LC) produced no effect on MAP-2þ cells when compared with similar concentrations of
ALC. (i) The 2-h treatment with ALC (300 mM), but not LC (300 mM) or vehicle, resulted in NF-kB p65 Lys310 acetylation in extracts of adult NPCs.
Expression levels of total p65 and b-actin were also evaluated as internal controls. Data are mean±SD of n¼ 3 experiments in triplicates. *Po0.05;
***Po0.001 vs vehicle-treated cells, yyyPo0.001 vs ALC-treated cells. Data in (a, d, f, g, and h) were analyzed by one-way ANOVA followed by Tukey’s post
hoc test, whereas data in (b, c, and e) were analyzed by Student’s t-test.
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Overall, these data demonstrated that ALC promoted
neuronal differentiation of adult hippocampal NPC at the
expenses of nonneuronal lineages and that neither neuro-
protective nor proliferative effects were involved in drug
activity in vitro.
NF-jB Pathway Activation and p65 Acetylation Are
Involved in ALC-Mediated Proneurogenic Effects
NF-kB transcription factors are involved in CNS functions,
including neuronal commitment and differentiation of adult
NPC (Grilli and Memo, 1997; Denis-Donini et al, 2005, 2008;
Koo et al, 2010). We then tested drugs interfering with
activation of the NF-kB pathway: JSH-23 and SN50, cell-
permeable blockers of nuclear translocation of NF-kB p65
and p50, respectively; SC-514, a reversible inhibitor of IkB
kinase 2 (IKK2). JSH-23 and SC-514 at 3 mM completely
abolished, whereas 10 mg/ml SN-50 partially counteracted
300 mM ALC-induced increase of MAP-2þ cells in NPC
cultures (F(9, 50)¼ 223.9, Po0.0001; Figure 1g). Post hoc
analysis confirmed that, when applied alone, JSH-23,
SC-514, and SN-50 had no effect on NPC differentiation
(5.35±0.44, 5.66±0.51, and 4.81±0.51, respectively) as
compared with vehicle (5.85±0.6; Figure 1g). Furthermore,
SN50M, the mutant counterpart of SN-50, did not affect
ALC activity on MAP-2þ cells (ALCþ SN50M: 16.86±0.7;
300 mM ALC: 17.1±0.9; Figure 1g). Overall, these data
suggested the involvement of NF-kB signaling in the
proneurogenic effects of ALC on adult hippocampal NPC.
Under similar experimental conditions, 300 mM and 1mM
L-carnitine (LC) had no effect on the generation of new
neurons (F(2, 18)¼ 3.340, NS; Figure 1h), unlike similar
concentrations of ALC (F(2, 18)¼ 322, Po0.0001;
Figure 1h), suggesting that acetylation may be involved in
ALC proneurogenic activity. By using an antibody against
Acetyl-NF-kB p65 (Lys310), we demonstrated that a 2-h
treatment of hippocampal NPC with 300 mM ALC promoted
p65 acetylation (Figure 1i). No p65 acetylation could be
observed when cells were treated with either vehicle or
300 mM LC (Figure 1i).
Group II mGlu Receptors, and in Particular the mGlu2
Subtype, Are Involved in ALC-Mediated Effects on Adult
Hippocampal NPC
The analgesic properties of ALC have been suggested to
involve drug-induced upregulation of mGlu2 receptor
expression in dorsal root ganglia neurons via acetylation
of NF-kB p65 (Chiechio et al, 2006). In our culture model,
the nonselective mGlu2/3 agonist LY379268 promoted
neurogenesis, as shown by a concentration-dependent
increase of MAP-2þ cells (F(6, 56)¼ 106.2, Po0.0001;
Figure 2a), with maximal effects elicited at 10 mM (%
increase over vehicle-treated cells: þ 164±21.7). As at mM
concentrations the agonist loses its selectivity for group II
and may activate group I and II mGlu receptors, we then
assessed whether the preferential mGlu2/3 antagonist
LY341495 (0.1–7.5 nM) was able to counteract ALC
proneurogenic effects on hippocampal NPC. In the presence
of 300 mM ALC, LY341495 caused a concentration-depen-
dent inhibition of drug-induced increase of MAP-2þ cells
(F(7, 64)¼ 94.97, Po0.0001; Figure 2b), with maximal
inhibition at 7.5 nM (Figure 2b). Alone, 7.5 nM LY341495
produced a statistically significant reduction in the percen-
tage of MAP-2þ cells when compared with vehicle-treated
cells (7.5 nM LY341495: 3.01±0.98; veh: 5.41±0.67,
Po0.05; Figure 2b) suggesting the presence of an endogen-
ous glutamatergic tone. In order to dissect the functional
contribution of specific group II receptor subtypes, we then
tested the selective mGlu2-positive allosteric modulator
(PAM), LY487379. Like ALC, the mGlu2 PAM (0.1–10 mM)
increased the percentage of MAP-2þ cells (F(5, 48)¼ 85.68,
Po0.0001; Figure 2c), with a maximal effect elicited at 1mM
(% increase over vehicle-treated cells: þ 192.8±28.8).
Representative images of MAP-2 immunolabeling experi-
ments further supported the effects of a 24-h treatment of
NPC with vehicle (Figure 2d), 300 mM ALC (Figure 2e),
10 mM LY379268 (Figure 2f), 1 mM LY487379 (Figure 2g),
7.5 nM LY341495 in presence of 300 mM ALC (Figure 2h), or
7.5 nM LY341495 alone (Figure 2i). We then tested whether
a 24-h treatment with ALC was able to upregulate expres-
sion of mGlu2 receptors in NPC cultures under differentiating
conditions (Figure 2j). Densitometric analysis demonstrated
that 300mM ALC increased mGlu2 protein levels (F(3, 8)¼
11.78, P¼ 0.0026; Figure 2j) (% increase over vehicle-treated
cells: 51±19.7) and that this effect was counteracted by
JSH-23, which had no effect alone. Under the same
experimental conditions, ALC treatment, in the presence or
absence of JSH-23, had no effect on mGlu3 protein levels
(F(3, 8)¼ 0.398, NS; Figure 2j). Altogether, these data
confirmed that ALC elicited its in vitro proneurogenic effects
via NF-kB p65-mediated upregulation of mGlu2 expression.
Chronic ALC Treatment Reverts UCMS-Induced
Depressive-Like Symptoms in Adult Mice
In rodents, unpredictable chronic mild stress (UCMS) has
good face validity and predictivity (Willner et al, 1987;
Mineur et al, 2006; Ibarguen-Vargas et al, 2008). A group of
22 adult male C57B/L6J mice was initially submitted to a
8-week UCMS regimen or maintained under control, non-
stressful conditions. The entire procedure is schematically
described in Figure 3a. Before starting, mice were analyzed
for 3% sucrose preference (SP), and, as expected, they
unequivocally preferred drinking sucrose over water (SP
480%). After 8 weeks of UCMS, one-way ANOVA revealed
a significant effect on SP (F(3, 40)¼ 31.09, Po0.0001). In
particular, a post hoc test showed that stressed mice had
significantly decreased SP values compared with their basal
preference (45±4% and 80±2%, Po0.001; Figure 3b),
whereas unstressed mice displayed no difference between
basal and 8-week values (78±3 and 76±2%, respectively,
NS; Figure 3c). Furthermore, SP between stressed and
unstressed mice was also significantly different (45±4 and
76±2%, respectively, Po0.001). In parallel, the 8-week
UCMS period increased immobility time of stressed
compared with unstressed mice both in the TST (77±9
and 35±5 s, respectively, Po0.001; Figure 3d) and in the
FST (80±5 and 51±6 s, respectively, Po0.05; Figure 3e)
paradigms. Altogether, these data confirmed that UCMS
elicited depressive-like symptoms in mice. Then, both
UCMS and control mice were divided into two groups that
were administered once daily s.c. either vehicle or ALC
(100mg/kg) for 21 days. Stress procedure continued to be
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applied during drug/vehicle treatment. The drug dose was
selected so to correspond to a recommended dose
(0.5 g/day) in humans. In addition, we confirmed that the
dose regimen resulted in increased plasma concentration
compared with vehicle-treated mice (297.5±28.7 and
19.5±1.8 mM in ALC- and vehicle-treated mice, Po0.001).
At the end of the drug administration period, mice were
retested for SP and immobility time in the TST and FST.
When SP was analyzed in experimental groups, a two-way
ANOVA revealed a significant effect of ALC treatment
(F(1, 18)¼ 20.82, P¼ 0.0002) and stressALC interaction
(F(1, 18)¼ 11.68, P¼ 0.0031) in the absence of significant
effect of stress (F(1, 18)¼ 0.844, NS). As shown in Figure 3b
and c, chronic ALC treatment reversed UCMS-induced
anhedonia (Figure 3b), with mice preferring sucrose
(76±2%) over water (Figure 3b). Conversely, ALC treat-
ment had no effect on SP in unstressed mice (66±2 and
61±4% in ALC- and vehicle-treated control mice, respec-
tively; Figure 3c). Importantly, chronic ALC administration
had no effect on total fluid consumption in naive animals
(data not shown). When we evaluated behavior in the TST,
we found a significant difference of stress (F(1, 18)¼ 9.309,
Figure 2 Group II mGlu receptors, and in particular the mGlu2 subtype, are involved in ALC proneurogenic effects. (a) The mGlu2/3 agonist LY379268
increased the percentage of MAP-2þ cells in adult NPC cultures in a concentration-dependent manner. (b) The preferential mGlu2/3 antagonist LY341495
counteracted the effects of ALC (300mM) on MAP-2þ cells. (c) The selective mGlu2 PAM LY487379 increased the percentage of MAP-2þ cells generated
from adult NPCs. (a–c) Data are mean±SD of n¼ 3 experiments in triplicates, analyzed by one-way ANOVA followed by Tukey’s post hoc test. *Po0.05;
**Po0.01; ***Po0.001 vs vehicle-treated cells and yyyPo0.001 vs ALC-treated cells. (d–i) Representative fluorescence microscopy images of
MAP-2 immunolabeling (green) in cells treated for 24 h with vehicle (d), 300 mM ALC (e), 10mM LY379268 (f), 1mM LY487379 (g), 7.5 nM
LY341495þ 300 mM ALC (h), and 7.5 nM LY341495 (i). Nuclei were counterstained with TOPRO (blue). Scale bar: 47.62 mm. (j) Immunoblot analysis and
quantification of mGlu2 and mGlu3 protein levels in adult hippocampal NPCs treated for 24 h with vehicle, 3mM JSH-23, 300 mM ALC in the presence of
vehicle, or 3mM JSH-23. Compared with vehicle, ALC treatment increased mGlu2 protein levels and JSH-23 counteracted these effects. No change in
mGlu3 protein levels was observed in the presence of any treatment condition. Data represent the mean±SD of n¼ 3 experiments from different cell
preparations, normalized by a-tubulin expressions and analyzed by two-way ANOVA followed by Bonferroni post hoc test. *Po0.05 vs vehicle-treated cells;
yyPo0.01 vs ALC-treated cells.
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P¼ 0.0069) and stressALC interaction (F(1, 18)¼ 4.488,
P¼ 0.048), whereas there was no overall effect of ALC
treatment (F(1, 18)¼ 4.192, P¼ 0.055). Post hoc analysis
revealed that ALC, but not vehicle, reverted stress-induced
increase in immobility (69±6 and 37±4 s for vehicle-
stressed and ALC-stressed mice, respectively, Po0.05;
Figure 3d). Similarly, in the FST, two-way ANOVA
confirmed a significant effect of ALC treatment
Figure 3 Chronic ALC treatment reverted UCMS-induced depressive-like behavior and upregulated mGlu2 protein levels in the hippocampi of stressed
mice. (a) Schematic representation of the experimental procedure. (b, c) Sucrose preference (SP) in (b) stressed (n¼ 11) and (c) unstressed (n¼ 11) mice.
Mice subjected to 8-week UCMS significantly reduced SP compared with their (b) baseline values (Po0.001) and with (c) unstressed mice (Po0.001).
(b) Chronic ALC treatment (100mg/kg, once a day, s.c.) reversed UCMS-induced anhedonia, with ALC-treated stressed mice (n¼ 6) displaying SP values
significantly higher than vehicle-treated stressed mice (n¼ 5; Po0.001). (c) ALC (n¼ 6) or vehicle treatment (n¼ 5) had no effect on unstressed mice. (d, e)
Behavioral analysis in the TST (d) and FST (e) following UCMS and after 21 days of saline/ALC treatment. After 8 weeks of stress, UCMS mice significantly
increased time (in seconds) spent in immobility in both TST (d) and FST (e) as when compared with unstressed, control (ctrl) mice. ALC was able to revert
stress-induced increase of immobility time in both TST (d) and FST (e), with ALC-treated UCMS mice immobility being significantly different from the
vehicle-treated UCMS mice in both TST and FST. No significant difference was observed between vehicle- and ALC-treated unstressed mice in both TST
(d) and FST (e). Data are mean±SD (*Po0.05, **Po0.01, ***Po0.001, yPo0.05, yyyPo0.001). (f–h) Representative experiments of immunoblot analysis
of mGlu2 (f), mGlu3 (g), and PAR-1 (h) levels in hippocampi of vehicle-treated unstressed, ALC-treated unstressed, vehicle-treated UCMS, and ALC-treated
UCMS mice. Densitometric values are mean±SD of mGlu2/a-tubulin, mGlu3/a-tubulin, and PAR-1/a-tubulin ratios from three independent experiments
(n¼ 4 mice/group). Data were analyzed by two-way ANOVA followed by Bonferroni post hoc test. **Po0.01 vs vehicle-treated stressed mice.
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(F(1, 18)¼ 5.387, P¼ 0.032) and stressALC interaction
(F(1, 18)¼ 19.37, Po0.0003), but no effect of stress
(F(1, 18)¼ 0.025, NS). The post hoc analysis showed that
ALC-treated stressed mice reduced their immobility as
compared with vehicle-treated stressed mice (22±5 and
93±17 s, respectively, Po0.001; Figure 3e). In addition,
immobility in ALC-treated stressed mice was significantly
reduced as compared with ALC-treated unstressed mice
(22±5 and 67±12 s, respectively, Po0.05). On the other
hand, no significant difference was observed between
vehicle- and ALC-treated unstressed mice in both TST
(Figure 3d) and FST (Figure 3e), whereas an increased
immobility time in vehicle-stressed compared with vehicle-
unstressed mice was present in both TST (69±5.62 and
30±10.57, respectively, Po0.01; Figure 3d) and FST
(93±17.2 and 45±4.1, respectively, Po0.05; Figure 3e).
We also observed no effect of chronic ALC administration
on body weight in unstressed or stressed mice (data not
shown). Altogether, these data demonstrated the efficacy of
chronic ALC administration in reverting depressive-like
symptoms induced by UCMS in adult mice.
Chronic ALC Treatment Increases mGlu2 Expression
and Adult-Born Neurons in Hippocampi of Stressed
Adult Mice
At the end of the entire experimental procedure, hippo-
campi were dissected for evaluation of mGlu2/3 protein
levels. Western blot analysis demonstrated that ALC
treatment significantly increased mGlu2 protein levels
(F(1, 8)¼ 13.39, P¼ 0.0064). ANOVA also showed a sig-
nificant effect between stressALC interaction
(F(1, 8)¼ 12.68, P¼ 0.0074) and stress (F(1, 8)¼ 5.581,
P¼ 0.04). On the other hand, mGlu3 protein levels were
not different in analyzing either stressALC interaction
(F(1, 8)¼ 1.05, P¼ 0.335) and stress or ALC treatment.
Specifically, a post hoc test revealed that mGlu2 and mGlu3
expression levels in vehicle-treated control and UCMS mice
were not significantly different (Figure 3f and g). Con-
versely, in stressed mice, ALC treatment resulted in
increased mGlu2, but not mGlu3, protein levels compared
with vehicle-treated mice (% increase: 86.6±8.8; Figure 3f
and g). Moreover, mGlu2 and mGlu3 expression levels were
not significantly different in ALC- and vehicle-treated
control mice (Figure 3f and g). As a negative control, we
verified that ALC had no effect on the expression levels of
an unrelated GPCR, PAR-1 (Figure 3h). An additional group
of mice was submitted to a 8-week UCMS regimen or
maintained under control conditions and stressed and
unstressed mice were then divided into two groups (n¼ 6
each) that were administered once daily either vehicle or
ALC (100mg/kg, s.c.) for 21 days. This time, the animals
were also injected with BrdU (150mg/kg, i.p.), for the first 5
days of drug treatment. At 21 days after the last drug/vehicle
injection, mice were transcardially perfused and their brains
processed for quantification of newly born BrdUþ /NeuNþ /
GFAP neurons in the dentate gyrus. Two-way ANOVA
revealed no significant difference in stressALC interac-
tion (F(1, 14)¼ 1.490, NS; Figure 4a–e) and of stress
(F(1, 14)¼ 2.036, NS), whereas a significant effect of ALC
treatment was observed (F(1, 14)¼ 29.20, Po0.0001). The
post hoc analysis confirmed a significantly increased
number of newborn neurons in ALC-treated stressed mice
compared with vehicle-treated stressed mice (1403±238
and 632±215, respectively, Po0.01; Figure 4c–e). The
number of new neurons was also increased in ALC-treated
unstressed compared with vehicle-treated unstressed mice
(1095±299 and 608±134, Po0.05; Figure 4a, b and e).
Conversely, no significant difference was reported between
vehicle-treated groups. Altogether, these data demonstrate
that similar to classical antidepressants, chronic adminis-
tration of ALC promotes hippocampal neurogenesis in both
stressed and unstressed mice. When tested, chronic ALC
treatment, compared with vehicle, had no significant effect
on the proliferation rate of neural progenitors, as assessed
by counting BrdUþ cells in the SGZ (2291±687 and
2379±327 in ALC and vehicle-treated mice, respectively,
P¼ 0.77) and in the GCL (2221±375 and 2241±439 in ALC
and vehicle-treated mice respectively, P¼ 0.93) of naive
animals killed 2 h after administration of the thymidine
analog (Figure 4f). These results suggest that the proneuro-
genic effects of ALC are not mediated by increased
proliferation of undifferentiated neural progenitors
in vivo. As antidepressants usually exert their proneuro-
genic effects under a chronic, but not acute or subchronic,
regimen (Malberg et al, 2000), we tested the effect of 1 or 7
days of ALC (and vehicle) administration on hippocampal
neurogenesis in naive adult mice (n¼ 7/group). A single
ALC treatment had no significant effect on the number of
new neurons, as compared with vehicle treatment
(726±187 and 866±82 in ALC- and vehicle-treated mice,
respectively; P¼ 0.21). Although no significant difference
was also observed in the number of BrdUþ /NeuNþ /
GFAP cells after 7 days of ALC/vehicle treatment
(1308±401 and 979±324 in ALC- and vehicle-treated mice,
respectively; P¼ 0.161), a two-way ANOVA revealed a
significant effect of duration of ALC treatment
(F(1, 17)¼ 6.697, P¼ 0.0192). In particular, a post hoc
analysis confirmed an increased number of BrdUþ /
NeuNþ /GFAP cells after 7 days compared with 1 day of
ALC treatment (Po0.05). No difference was observed
between 1 and 7 days in vehicle-treated mice.
DISCUSSION
Several double-blind, placebo-controlled studies demon-
strated that ALC treatment has beneficial effects in major
depression and dystymia (Bella et al, 1990; Garzya et al,
1990; Gecele et al, 1991; Zanardi and Smeraldi, 2006). Here
we show, for the first time, that ALC promotes neuronal
differentiation of adult hippocampal progenitors in vitro
without affecting proliferation or survival rate. Recent work
demonstrated the involvement of upregulated mGlu2 gene
expression in ALC-mediated analgesic activity via NF-kB
p65 acetylation (Chiechio et al, 2009). Also in our
experimental model, at least in vitro, the NF-kB pathway
was responsible for mediating ALC proneurogenic effects,
as interfering with its activation abolished drug activity.
More specifically, ALC resulted in acetylation of p65 at
Lys(310) in NPC cultures. Moreover, ALC treatment of
hippocampal NPC resulted in a significant upregulation of
mGlu2 protein levels and this effect was abolished by
inhibiting p65 nuclear translocation. It is also interesting
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that in our culture model mGlu2 activation by a selective
positive allosteric modulator promoted neurogenesis,
whereas a preferential mGlu2/3 antagonist counteracted
ALC-mediated proneurogenic effects. We are aware of the
interpretative limitations of data generated by single mGlu
ligands, as the distinct functions of mGlu2 and mGlu3 are
not fully understood. For this reason, even if we did not
observe significant effects of ALC on mGlu3 protein levels,
at present we cannot exclude that this receptor subtype,
which has been shown to be functionally expressed by adult
NPC (Di Giorgi-Gerevini et al, 2005; Ciceroni et al, 2010),
may also be involved. We also proved that chronic ALC
reverted depressive-like behavior in a predictive animal
model. Importantly, the utilized dose corresponds to the
lowest recommended dose in humans (0.5 g/day) (Reagan-
Shaw et al, 2008). Furthermore, this dose regimen effectively
increased plasma levels of ALC in chronically treated mice,
as previously shown (Schaevitz et al, 2012). We also
Figure 4 Chronic ALC treatment increased hippocampal neurogenesis in vivo. (a–d) Representative confocal microscopy images of immunofluorescent
labeling for BrdU (blue)/NeuN (red)/GFAP (green) of hippocampal sections in control (Ctrl; a, b) and stressed (UCMS; c, d) mice subcutaneously injected
with vehicle (a, c) or 100mg/kg ALC (b, d) for 21 days. White arrowheads indicate BrdUþ /NeuNþ /GFAP cells within the dentate gyrus. Scale bar: 75mm.
(e) Quantitative analysis of BrdUþ /NeuNþ /GFAP cells in stressed and unstressed mice. The number of newly born hippocampal neurons was significantly
increased in the granular cell layer (GCL) of ALC-treated stressed and unstressed mice compared with vehicle-treated stressed and unstressed mice,
respectively. Data are expressed as mean±SD of n¼ 7 mice/group, and were analyzed by two-way ANOVA followed by Bonferroni post hoc test. *Po0.05
vs vehicle-treated unstressed mice; ##Po0.01 vs vehicle-treated stressed mice. (f) Proliferation rate in the dentate gyrus of mice treated with 100mg/kg ALC
or vehicle for 21 days. The number of BrdUþ cells in the subgranular zone (SGZ) and GCL was not significantly different in vehicle- and ALC-treated mice
killed 2 h after BrdU administration. Data are expressed as mean±SD of n¼ 7 mice/group.
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demonstrated that chronic ALC treatment correlated with
increased mGlu2 protein levels in the hippocampi of stressed
but not unstressed mice. The role of group II mGlu receptors
in depression is currently debated, as both mGlu2/3 agonists
and antagonists can produce antidepressive effects in rodent
models (Chaki et al, 2013). This apparent paradox could in
part rely on the fact that mGlu2/3 subtypes may play
different functions and/or may be differentially (de)regu-
lated in depressive disorders. Although at present we have
no information as to where mGlu2 upregulation may affect
in the hippocampal circuit, it is known that these receptors
are in the preterminal regions of perforant pathway axons
and mossy fibers, where they have little effect on glutamate
release under normal conditions but they may potentiate a
negative feedback control under conditions of excessive
glutamate release, which is associated with depression
(Bonanno et al, 2005; Sanacora et al, 2008). Interestingly,
THIIC, a novel potent and selective allosteric modulator of
mGlu2, recently demonstrated robust antidepressant proper-
ties in vivo (Fell et al, 2011), suggesting a contribution of
that subunit to the pathophysiology of depression. We also
demonstrated that chronic ALC administration increased
formation of adult-born neurons in the hippocampus of
adult mice in vivo, a property shared by classical
antidepressants. Unlike mGlu2 effects, chronic ALC treat-
ment correlated with increased hippocampal neurogenesis in
both stressed and unstressed mice. In this respect, ALC is
similar to classical antidepressants that also promote
neurogenesis in naive mice when chronically administered
(Malberg et al, 2000). Interestingly, unlike other classical
antidepressants (Santarelli et al, 2003), ALC did not affect
proliferation of neural hippocampal progenitors in vitro and
in vivo. Finally, like classical antidepressants, ALC did not
significantly increase neurogenesis when administered
acutely (1 day) or subchronically (7 days). Although no
significant effects were reported between vehicle and ALC,
we observed a significant increase in the number of newly
generated neurons in hippocampi of 7-day ALC-treated
compared with 1-day ALC-treated mice. Future experiments
should investigate whether these observations may underlie
a more rapid onset of proneurogenic effects of ALC
compared with classical antidepressants.
The involvement of NF-kB p65 acetylation in the
proneurogenic and potentially antidepressive effects of
ALC is in apparent contrast with the observation that p65
activation has been proposed to mediate decreased
hippocampal neurogenesis in response to chronic stress
and interleukin-1 (Koo et al, 2010). The fact that both
induction and inhibition of adult neurogenesis may rely on
NF-kB p65 is likely to reflect the complexity within the
NF-kB signaling pathway. Indeed, NF-kB proteins represent
a family of several transcription factors whose members,
including p65, can combine to form hetero- and homo-
dimers of different composition, which can be differentially
activated in a given cell type and exert different, even
opposite, functions through activation of different sets of
gene targets (Grilli and Memo, 1997). In addition, little
information is currently available on the contribution of
p65 acetylation to the NF-kB-mediated transcriptional
program. In this respect, in the future it will be important
to identify the full set of gene targets activated by ALC in the
hippocampus.
Although at present we cannot prove a causal relationship
between ALC behavioral effects and drug-mediated effects
on mGluR2 expression and neurogenesis in vivo, it is
remarkable that ALC-mediated proneurogenic and anti-
depressant activity may be elicited through the mechanism
mediating its analgesic effects. Interestingly, upregulation of
mGlu2, via acetylation of NF-kB p65, is also triggered by
other analgesic drugs such as MS-275 and SAHA, which are
histone deacetylase (HDAC) inhibitors (Chiechio et al,
2009). In addition, HDAC inhibitors are also proneurogenic
(Kim et al, 2009) and elicit antidepressant-like effects
(Gundersen and Blendy, 2009; Covington et al, 2009).
Altogether, these and our observations would potentially
imply that mGlu2 upregulation, via p65 acetylation, may
also be involved in these pharmacological activities of
HDAC inhibitors.
Of course, at present, we cannot exclude additional
mechanisms participating in the antidepressant effects of
ALC, including modulation of the glia-derived growth factor
artemin (Di Cesare Mannelli et al, 2011) and increased
hippocampal levels of noradrenaline (Smeland et al, 2012).
In conclusion, here we propose novel mechanisms that
could be potentially involved in the antidepressant effects of
ALC in humans, namely upregulation of mGlu2 levels and
promotion of neurogenesis in the hippocampus, via NF-kB
p65 acetylation. The demonstration that ALC is an
antidepressant in a predictive model of disease may have
clinical relevance. ALC is indeed very well tolerated in
humans (Thal et al, 1996, 2000) and it could be employed in
patient subpopulations who are sensitive to toxicity
associated with currently available antidepressants.
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